Head and Neck Cancer
Conditions
Interventions
18F-FRP170-PET/CT and 18F-FMISO-PET/CT are conducted at Southern TOHOKU hospital as an outpatient. 18F-FRP170 is administered in a rang e of 185-370 MBq with a concentration of less than 4 MBq/kg of a
Sponsors
Takai Yoshihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patient or substitute for patient has voluntarily signed the informed consent 2. Patients' age 20==3,000/mm3 and =1,500/mm3 Platelets>=100,000/mm3 AST(GOT) =<2.5x the ULN for the reference lab ALT(GPT) =< 2.5 x the ULN for the reference lab Creatinine =<1.5mg /dL 10. Patients have no clinically sig nificant abnormalities in 12-lead ECG for the past 6 months
Exclusion criteria
Exclusion criteria: 1. Patients with significant complications. 1) Poorly-controlled diabetes mellitus 2) Poorly-controlled hypertension 3) Pulmonary disease with respiratory insufficiency 4) Renal disease(chronic renal failure,acute renal failure,nephrotic syndrome,artifical dialysis,etc) 5) Heart disease with heart failure symptoms 2. Patients who were enrolled in this clinical study or the other study within 3months before the initial informed consent or who are participating and will participate in other clinical study. 3. Patients who are pregnancy and want to become pregnant and male who want his partner to become pregnant. 4. Patients with complications of mental disease or psychological symptom who can't be participated in this clinical study or who are taking antipsychotics. 5. Patients with poorly-controlled epilepsy. 6. Patients whom a principal investigator or sub-investigator determined ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To obtain the following parameters at 1 h, 2 h, and 4 h after drug administration from 18F-FRP170-PET and 18F-FMISO-PET PET studies. 1) SUVmax 2) T/N (tumor/normal tissue ratio, SUVtumor/SUVnormal tissue) 3) T/B (tumor/blood ratio, SUVtumor/SUVblood) 4) T/M (tumor/muscle ratio, SUVtumor/SUVmuscle), | — |
Secondary
| Measure | Time frame |
|---|---|
| Time-Activity Curves0-30min after injection | — |
Contacts
Public ContactEtsuko Sakai
Southern TOHOKU Research Institute for Neuroscience
Outcome results
None listed